Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions

Area of Science:

• Oncology
• Metabolic Medicine
• Clinical Pharmacology

Background:

• Cancer cachexia (CC) is a complex metabolic syndrome characterized by weight loss, anorexia, and systemic inflammation.
• Despite advances, CC remains underdiagnosed and undertreated, significantly impacting patient quality of life, treatment tolerance, and survival.
• Effective management requires early identification of core symptoms like weight loss and poor appetite.

Purpose of the Study:

• To review current understanding and management strategies for cancer cachexia.
• To highlight emerging therapeutic agents and future directions in CC treatment.
• To emphasize the importance of a multimodal, interdisciplinary approach to CC care.

Main Methods:

• Literature review of mechanisms, diagnosis, and treatment of cancer cachexia.
• Discussion of current supportive care interventions, including nutritional support and management of associated symptoms.
• Analysis of pharmacologic agents, including approved drugs (e.g., Anamorelin) and investigational therapies (e.g., Espindolol, anti-GDF-15 antibodies).

Main Results:

• Anamorelin, a ghrelin receptor agonist, demonstrated improvements in lean body mass, weight, and appetite-related quality of life in Phase III trials in Japan.
• Current recommendations involve addressing contributing conditions, managing nutrition-impact symptoms, and judicious use of pharmacologic agents.
• Investigational agents targeting GDF-15 and other pathways show promise for future CC treatment.

Conclusions:

• Cancer cachexia necessitates early recognition and comprehensive management strategies.
• Pharmacologic interventions, particularly Anamorelin, represent a significant advancement in CC treatment.
• Future CC management will likely involve a combination of targeted therapies integrated into a multimodal, interdisciplinary care model including exercise and nutrition.